Heidi raises US$340M to expand AI agents in healthcare

Heidi has secured US$340 million in new funding as the Melbourne-based healthcare AI company expands its platform from clinical documentation into supervised tasks across health systems.

The funding comprises a US$100 million Series C equity round led by Blackbird and a separate US$240 million growth investment led by General Catalyst's Customer Value Fund. Existing investors including Phoenix Court, Point72 Private Investments and Headline also participated in the Series C.

The Series C values Heidi at US$900 million. The combined investment will support expansion across global health systems, development of AI agents for work around patient visits and further clinical safety and regulatory work.

Moving beyond

"From the day I started Heidi, the ambition was always bigger than writing doctor's notes. I imagined that AI would sit alongside clinicians and complete real work under their supervision." said Dr Thomas Kelly, Co-founder and CEO, Heidi. "That's the shift we're now making: from documenting care to helping clinicians act on it. This round is about getting an AI Care Partner to every doctor in the world, and putting clinicians back at the center of care with their patients."

Heidi said its platform has supported more than 175 million patient visits since its launch, compared with 73 million at its Series B funding round. The company said the platform has also supported more than 67 million clinical hours.

The platform is being used in 190 countries and supports 110 languages. Heidi reported annual recurring revenue of US$50 million in April 2026, up from US$1 million two years earlier.

The company is targeting work beyond medical note-taking as healthcare systems face pressure from staff shortages and growing clinical demand. It said its AI Care Partner is intended to support administrative and clinical tasks throughout the working day.

Health systems

Heidi has expanded its presence across public and private healthcare organisations since its Series B round. The company said its enterprise activation rate is about 62%.

In Australia, deployments include The Royal Children's Hospital Melbourne, Children's Health Queensland Hospital and Health Service and Metro South Health.

In New Zealand, Heidi said it has been deployed across every emergency department in the country. In the UK, it was selected as the sole supplier for NHS England Midlands, which Heidi described as the largest clinical AI procurement in NHS history.

In the US, the platform is used by Beth Israel Lahey Health, one of the largest health systems in Massachusetts.

The company has also expanded across other markets. It said Swiss Medical Network has deployed the platform in Switzerland, while its Canadian operations include a vendor-of-record appointment with Supply Ontario and an integration with Accuro EMR.

In Asia, Heidi has established regional hubs in Hong Kong and Singapore and has set up a Japanese entity with in-country data hosting infrastructure. It has also been selected by KPJ Healthcare for a rollout across 27 hospitals in Malaysia.

Clinical agents

Heidi has expanded its product range beyond its AI scribe. Heidi Evidence provides clinical guidelines at the point of care and has handled more than 10 million queries since its launch in March 2026.

The company has also introduced Remote, a wearable device designed for audio capture across settings including surgery and community clinics. Dictate provides voice-to-text capabilities.

The next stage of development centres on AI agents that can work through healthcare workflows and return tasks for clinician review. Heidi said clinicians will remain responsible for decisions made through these systems.

The funding will also be used for clinical evidence, quality management systems and regulatory submissions required for agentic healthcare applications.

Heidi said its transcription and note-generation systems run predominantly on technology developed in-house. The company said this allows it to select different approaches for individual clinical tasks while managing accuracy, latency and computing costs.

Safety controls

The company said its clinical research team conducts testing and validation before products are made available to clinicians. It plans to apply the same process to its agentic AI capabilities.

"We've backed Tom and the team since their pre-seed in 2021 and our conviction is greater than ever. The healthcare deficit won't be solved with generic AI solutions that clinicians ignore. Heidi invested early in deeply understanding what clinicians want, building its own models and training capability to deliver this. This approach has earnt them the right to capture valuable downstream workflows in the most rigorous clinical settings globally," said Michael Tolo, General Partner, Blackbird.

Heidi said the new product capabilities for supervised clinical tasks will not be available in the UK and EU.